Lexaria Bioscience (LEXX) Gross Margin (2017 - 2026)

Lexaria Bioscience has disclosed Gross Margin across 10 years of filings, most recently posting 100.0% for Q1 2026.

• Gross Margin for Q1 2026 came in at 100.0%, changed 0.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 100.0% (up 52.0% YoY), and the FY2025 annual result was 99.61%, up 65.0% from the prior year.
• Gross Margin came in at 100.0% for Q1 2026 at Lexaria Bioscience, roughly flat from 100.0% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 571.57% in Q1 2023 to a low of 48.61% in Q3 2022.
• The 5-year median for Gross Margin is 100.0% (2023), against an average of 121.46%.
• Across the five-year window, Gross Margin jumped 49240 bps in 2023 and slumped 47157 bps in 2024, its largest moves.
• Lexaria Bioscience's Gross Margin stood at 83.84% in 2022, then advanced by 15 bps to 96.81% in 2023, then climbed by 2 bps to 98.52% in 2024, then advanced by 2 bps to 100.0% in 2025, then changed by 0 bps to 100.0% in 2026.
• The last three Gross Margin figures came in at 100.0% (Q1 2026), 100.0% (Q3 2025), and 100.0% (Q2 2025), per Business Quant data.